BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 26996555)

  • 1. Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer.
    Lee M; Chang MY; Yoo H; Lee KE; Chay DB; Cho H; Kim S; Kim YT; Kim JH
    Yonsei Med J; 2016 May; 57(3):580-7. PubMed ID: 26996555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
    Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.
    Zwakman N; van de Laar R; Van Gorp T; Zusterzeel PL; Snijders MP; Ferreira I; Massuger LF; Kruitwagen RF
    J Gynecol Oncol; 2017 Jan; 28(1):e7. PubMed ID: 27670261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
    Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH
    J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between CA125 levels after sixth cycle of chemotherapy and clinical outcome in advanced ovarian carcinoma.
    Gadducci A; Menichetti A; Guiggi I; Notarnicola M; Cosio S
    Anticancer Res; 2015 Feb; 35(2):1099-104. PubMed ID: 25667499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring ovarian cancer patients during chemotherapy and follow-up with the serum tumor marker CA125.
    Abu Hassaan SO
    Dan Med J; 2018 Apr; 65(4):. PubMed ID: 29619933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CA125 normalization within 60 days as an independent prognostic factor for patients with advanced epithelial ovarian cancer.
    Liao YC; Ou YC; Wu CH; Fu HC; Tsai CC; Lin H
    Cancer Biomark; 2021; 32(4):559-567. PubMed ID: 34397404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study.
    Bai H; Sha G; Xiao M; Gao H; Cao D; Yang J; Chen J; Wang Y; Zhang Z; Shen K
    Oncotarget; 2016 Mar; 7(13):15566-76. PubMed ID: 26863639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
    Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
    Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.
    van Altena AM; Kolwijck E; Spanjer MJ; Hendriks JC; Massuger LF; de Hullu JA
    Gynecol Oncol; 2010 Nov; 119(2):265-9. PubMed ID: 20797777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report.
    Skaznik-Wikiel ME; Sukumvanich P; Beriwal S; Zorn KK; Kelley JL; Richard SD; Krivak TC
    Int J Gynecol Cancer; 2011 Aug; 21(6):1013-7. PubMed ID: 21792011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Carpén O; Matomäki J; Oksa S; Virtanen J; Grénman S
    Tumour Biol; 2014 Dec; 35(12):12389-95. PubMed ID: 25190018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer.
    Yang ZJ; Zhao BB; Li L
    J Ovarian Res; 2016 Sep; 9(1):57. PubMed ID: 27629537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic value of CA125 half-life and early normalization during chemotherapy in advanced ovarian tumors: results of a multicentric French study].
    Riedinger JM
    Bull Cancer; 2007 Mar; 94(3):287-95. PubMed ID: 17371771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic Analysis of CA125 Decline During Neoadjuvant Chemotherapy in Patients with Epithelial Ovarian Cancer as a Predictor for Platinum Sensitivity.
    Pelissier A; Bonneau C; Chéreau E; DE LA Motte Rouge T; Fourchotte V; Daraï E; Rouzier R
    Anticancer Res; 2016 Apr; 36(4):1865-71. PubMed ID: 27069172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Potential value of CA125 kinetic monitoring in the initial management of advanced epithelial ovarian cancer].
    Vignot S; Brochet C; Debord C; Lauratet B; Bernard M
    Ann Biol Clin (Paris); 2011; 69(5):597-604. PubMed ID: 22008142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated Preoperative CA125 or CA19-9 in Borderline Ovarian Tumors: Could It Be Suggestive of Advanced Stage or a Poor Prognosis?
    Song T; Lee DH; Jung YW; Yun BS; Seong SJ; Choi CH; Lee JW; Bae DS; Kim BG
    Gynecol Obstet Invest; 2018; 83(1):45-51. PubMed ID: 28571024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer.
    Paek J; Lee SH; Yim GW; Lee M; Kim YJ; Nam EJ; Kim SW; Kim YT
    Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):338-42. PubMed ID: 21683503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High grade, advanced, serous ovarian cancer with low serum CA125 levels.
    Asali A; Haj-Yehia N; Zehavi T; Perry T; Beiner M; Fishman A; Kadan Y
    J Obstet Gynaecol; 2021 Oct; 41(7):1107-1111. PubMed ID: 33427544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.